Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease

Journal of Clinical Pathology

Volumn 60, Issue 4, 2007, Pages 415-418

  Butscheid, M ^a,b   Hauptvogel, P ^c   Fritz, P ^c   Klotz, U ^b   Alscher, D M ^c  

^a Dr Margarete Fischer Bosch Institute of Clinical Pharmacology ^*  (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; GALECTIN 3;

ARTICLE; CELL PROTECTION; CYTOTOXICITY; GLYCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

BILE DUCTS, INTRAHEPATIC; BIOPSY; GALECTIN 3; GLYCOSYLATION END PRODUCTS, ADVANCED; HEPATOCYTES; HUMANS; IMMUNOENZYME TECHNIQUES; KUPFFER CELLS; LIVER; LIVER DISEASES;

EID: 34247132569     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.032391     Document Type: Article

References (25)

1. Kasper M, Funk RH. Age-related changes in cells and tissues due to advanced glycation end products (AGEs). Arch Gerontol Geriatr 2001;32:233-43.
2. Horiuchi S. The liver is the main site for metabolism of circulating advanced glycation end products. J Hepatol 2002;36:123-5.
3. Ahmed MU, Brinkmann Frye E, Degenhardt TP, et al. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997;324:565-70.
4. Hayase F, Nagaraj RH, Miyata S, et al. Aging of proteins: immunological detection of a glucose-derived pyrrole formed during maillard reaction in vivo. J Biol Chem 1989;264:3758-64.
5. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 1989;264:21597-602.
6. Lo TW, Westwood ME, McLellan AC, et al. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J Biol Chem 1994;269:32299-305.
7. Reddy S, Bichler J, Wells-Knecht KJ, et al. N epsilon-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995;34:10872-8.
8. Ikeda K, Higashi T, Sano H, et al. N (epsilon)- (carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996;35:8075-83.
9. Sebekova K, Kupcova V, Schinzel R, et al. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J Hepatol 2002;36:66-71.
10. Vlassara H, Fuh H, Makita Z, et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 1992;89:12043-7.
11. Vlassara H, Striker U, Teichberg S, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-8.
12. Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997;94:13915-20.
13. Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46.
14. Stern DM, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002;1:1-15.
15. Horiuchi S, Higashi T, Ikeda K, et al. Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes 1996;45:S73-6.
16. Ohgami N, Nagai R, Ikemoto M, et al. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci 2001;947:350-5.
17. Li YM, Mitsuhashi T, Wojciechowicz D, et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996;93:11047-52.
18. Vlassara H, Li YM, Imani F, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1:634-46.
19. Iacobini C, Amadio L, Oddi G, et al. Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol 2003;14:S264-70.
20. Zhu W, Sano H, Nagai R, et al. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun 2001;280:1183-8.
21. Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004;9:305-28.
22. Hsu DK, Dowling CA, Jeng KC, et al. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999;81:519-26.
23. Iacobini C, Oddi G, Pugliese G, et al. Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice. Am J Physiol Renal Physiol 2005;289:F611-21, e-pub ahead of print.
24. Shimonishi T, Miyazaki K, Kono N, et al. Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 2001;32:302-10.
25. Smedsrod B, Melkko J, Araki N, et al. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 1997;322:567-73.